Tirzepatide, a dual GLP-1/GIP receptor agonist, amplifies these effects through synergistic receptor activation, demonstrating 12.9 kg average weight loss in SURPASS trials whilst improving hepatic inflammation markers in patients with obesity-related non-alcoholic steatohepatitis (NASH) [61,62]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.